Survival Benefits of Palbociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
| Author | Nasrin Mansouri | en |
| Author | Seyed Ghasem Mirbahari | en |
| Author | Roya Zandian | en |
| Author | Negin Farshchian | en |
| Issued Date | 2025-12-31 | en |
| Abstract | Context: Endocrine therapy remains the standard of care for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC), but its efficacy is limited in patients with prior endocrine exposure. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), such as palbociclib, have emerged as a promising strategy to enhance treatment outcomes. Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of palbociclib combined with endocrine therapy (ET) versus endocrine therapy alone in improving survival outcomes. Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science up to November 9, 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials (RCTs) comparing palbociclib plus ET with ET alone or placebo plus ET in HR+/HER2– advanced or metastatic BC patients were included. Outcomes assessed were progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled. Results: Seven RCTs, including 1,758 patients, met inclusion criteria. Pooled analysis demonstrated that palbociclib combined with ET significantly improved PFS compared with ET alone (HR = 0.492; P < 0.001). A trend toward improved OS was observed (HR = 0.883; P = 0.075), though this did not reach statistical significance. Subgroup analyses and bias assessments confirmed consistent efficacy across populations and low risk of methodological bias, with no evidence of publication bias. Conclusions: Palbociclib combined with ET provides substantial improvements in PFS and demonstrates a favorable trend in OS for patients with HR+/HER2– advanced BC. | en |
| DOI | https://doi.org/10.5812/jrps-168222 | en |
| URI | https://brieflands.com/journals/jrps/articles/168222 | en |
| Keyword | Breast Cancer | en |
| Keyword | Palbociclib | en |
| Keyword | CDK4/6i | en |
| Keyword | Endocrine Therapy | en |
| Keyword | Progression-Free Survival | en |
| Publisher | Brieflands | en |
| Title | Survival Benefits of Palbociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Trials | en |
| Type | Systematic Review | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jrps-13-1-168222-publish-pdf.pdf
- Size:
- 922.59 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF